Edwards Lifesciences Attracts Major Institutional Bet Ahead of Key 2026 Catalysts
A sophisticated, high-conviction options trade by a large investor signals strong confidence in Edwards Lifesciences' fundamentals, with a potential breakout eyed for early 2026 tied to regulatory milestones and sustained growth in its mitral valve business.